Our findings demonstrate that the Egr2/3-mediated programme is required for the homeostatic fitness of PD-1high MP CD4 cells both to enable their participation in adaptive responses and control autoimmune inflammation, which suggests that modulation of the Egr2/3 programme may provide a new avenue for immune modulation therapy for cancer, chronic infections, and autoimmune diseases. This evidence concerns the gene CD4 and cancer.